The Fly | AZTA

Azenta

· AZTA

Dashboard

Financials

KPIs

Ratios

Transcripts

Valuation

Over a week ago

Azenta sees FY26 revenue $603-$621M, consensus $624.07M

AZTA

May 5, 4:45 PM

Azenta reports Q2 non-GAAP EPS (4c), consensus 14c

AZTA

May 5, 4:43 PM

Azenta price target lowered by $10 at Evercore ISI, here's why

AZTA

Apr 6, 8:02 AM

Azenta price target lowered by $5 at Jefferies, here's why

AZTA

Apr 1, 1:59 PM

Azenta, Frontier Space announce strategic partnership

AZTA

Feb 9, 4:10 PM

Azenta price target lowered by $5 at Evercore ISI, here's why

AZTA

Feb 5, 8:14 AM

Azenta price target lowered by $9 at TD Cowen, here's why

AZTA

Feb 4, 2:08 PM

Azenta backs FY26 organic revenue view 3%-5%

AZTA

Feb 4, 6:58 AM

Azenta reports Q1 EPS 9c, consensus 13c

AZTA

Feb 4, 6:57 AM

Azenta price target raised by $4 at TD Cowen, here's why

AZTA

Jan 8, 9:35 AM

Evercore ISI upgrades four, downgrades six in MedTech and Tools

Jan 5, 6:35 AM

Evercore ISI gets more bullish on Azenta, upgrades shares

AZTA

Jan 5, 6:19 AM

Azenta enters agreement for sale of B Medical Systems to THELEMA for $63M

AZTA

Dec 29, 8:03 AM

Azenta price target raised by $2 at Needham, here's why

AZTA

Dec 19, 7:46 AM

Azenta authorizes $250M share repurchase program

AZTA

Dec 10, 12:44 PM

Azenta to host investor day

AZTA

Dec 10, 10:43 AM

Azenta price target raised by $10 at Raymond James, here's why

AZTA

Nov 25, 11:33 AM

Nephron Research gets more bullish on Azenta, upgrades shares

AZTA

Nov 24, 7:24 AM

What You Missed On Wall Street On Friday

+27

Nov 21, 4:14 PM

Midday Fly By: Bitcoin slides, Lilly hits $1T market cap

+28

Nov 21, 12:02 PM

Morning Movers: AnaptysBio sinks after GSK sues

+10

Nov 21, 8:58 AM

Azenta sees FY26 organic revenue up 3%-5%

AZTA

Nov 21, 6:51 AM

Azenta revises previously issued financial statements

AZTA

Nov 21, 6:50 AM

Azenta reports Q4 EPS 21c, consensus 20c

AZTA

Nov 21, 6:48 AM

Integrated Workflow Solutions: Azenta provides a comprehensive suite of products and services spanning automated sample management to genomic services, offering customers a more streamlined and integrated solution for complex life science research workflows.

High Switching Costs and Customer Stickiness: Once Azenta's automated sample storage systems and data management platforms are embedded within a customer's laboratory infrastructure, the time, cost, and disruption associated with switching to a competitor's system are substantial, fostering strong customer retention.

Market Leadership in Automated Sample Management: Azenta holds a strong global position and recognized brand in automated biological sample management, built on an extensive installed base, specialized expertise in cryogenics, and advanced robotics.

Intense Market Competition: Azenta operates in highly competitive markets for life sciences tools, consumables, and services, facing pressure from established players and new entrants that could impact pricing, market share, and profitability.

Technological Obsolescence: The life sciences industry is characterized by rapid technological advancements; Azenta's products and services could become outdated if they fail to innovate and keep pace with emerging technologies, potentially leading to reduced demand.

Regulatory Compliance Risks: Operating globally and within regulated industries (e.g., healthcare, research) subjects Azenta to complex and evolving laws and regulations, including data privacy, quality standards, and environmental controls, with non-compliance potentially leading to significant penalties or reputational damage.